Molecular structure of Niraparib, CAS Number: 1038915-60-4
Niraparib (CAS 1038915-60-4)
Alternate Names:
MK-4827
CAS Number:
1038915-60-4
Molecular Weight:
320.39
Molecular Formula:
C19H20N4O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Niraparib (CAS 1038915-60-4) References
- Niraparib restrains prostate cancer cell proliferation and metastasis and tumor growth in mice by regulating the lncRNA MEG3/miR-181-5p/GATA6 pathway. | Cheng, J., et al. 2023. PeerJ. 11: e16314. PMID: 38047026
- Integrated transcriptome and cell phenotype analysis suggest involvement of PARP1 cleavage, Hippo/Wnt, TGF-β and MAPK signaling pathways in ovarian cancer cells response to cannabis and PARP1 inhibitor treatment. | Shalev, N., et al. 2024. Front Genet. 15: 1333964. PMID: 38322025
- PARP inhibitors suppress tumours via centrosome error-induced senescence independent of DNA damage response. | Yue, W., et al. 2024. EBioMedicine. 103: 105129. PMID: 38640836
- A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells. | Bulanova, D., et al. 2024. Sci Adv. 10: eadj1564. PMID: 38781347
- PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation. | Muvaffak, A. and Coleman, KG. 2024. Front Oncol. 14: 1380633. PMID: 38807759
- Niraparib enhances antitumor immunity and contributes to the efficacy of PD-L1 blockade in cervical cancer. | Chang, J., et al. 2024. J Cancer Res Clin Oncol. 150: 304. PMID: 38869633
- PARP inhibitors in non-ovarian gynecologic cancers. | Fernandes, I., et al. 2024. Ther Adv Med Oncol. 16: 17588359241255174. PMID: 38882441
- Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib. | Mentzel, J., et al. 2024. Int J Mol Sci. 25: PMID: 38891817
- Real-world TRAE association between niraparib and platinum-based chemotherapy. | Wang, L., et al. 2024. Front Oncol. 14: 1390820. PMID: 38952544
Inhibitor of:
β-defensin 35, 4930547N16Rik, AK7, BABAM1, BRCA2, BRCAA1, C12orf32, C17orf53, C20orf196, C9orf119, CCDC98, CXXC5, DNB5, DNLZ, eRF1, FAN, GTBP, H2-10, KIAA1267, MND1, MRG1, Olr1156, Olr119, Olr1218, Olr1245, Olr180, Olr184, Olr517, Olr532, Olr668, Olr696, Olr716, Ovarian Carcinoma-associated Antigen, PALB2, PAMR1, PAR4, Paraxis, PARN, PARP L, PARP-1, PARP-10, PARP-11, PARP-12, PARP-14, PARP-15, PARP-16, PARP-2, PARP-8, PIERCE 1, Pma, PMS1, PRK2, PRP19, PSG9, RECA-1, REV1, RNF8, RuvC, TDE1, TDP2, TNRC18, TRABID, V1RH17, XRCC2, and XRCC6BP1.Activator of:
ARH3, DNA pol θ, DNAH5, FIGNL1, HPF1, MPHOSPH8, Msh6, PARP-4, and PARP-9.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Niraparib, 10 mg | sc-507492 | 10 mg | $150.00 |